The LifeViz® Scientific Compendium gathers 54 peer-reviewed publications and conference proceedings (2011–2026) in which independent investigators used 3D stereophotogrammetry to measure clinical results objectively: volume, surface, wrinkle depth, roughness, scar size, lesion size or wound area. Many of these studies used LifeViz® 3D imaging.
| Item | Detail |
|---|---|
| Studies | 54 |
| Publication span | 2011–2026 |
| Journals and proceedings | 31 |
| Clinical fields | Aesthetics (35 studies), Dermatology (14), Wounds (5) |
| What is measured | Volume, surface, wrinkle depth, skin roughness, scar volume, lesion size, wound area |
| Imaging solutions referenced | LifeViz Mini (3D facial), LifeViz Micro (skin micro-topography), LifeViz Infinity (3D body), DermaViz / LifeViz 2D (skin analysis) |
3D stereophotogrammetry reconstructs the shape of the face, body or skin surface from images captured at the same moment from different angles. Because every scan is standardized and calibrated, the same area can be measured before and after treatment, in millimetres or millilitres, and compared over time. It replaces subjective assessment (scales, visual impressions) with reproducible, measured data.
These are findings reported by the original authors. Several studies evaluate third-party treatments; their inclusion does not imply endorsement of those products.
Dermal fillers (cheeks, midface, lips, temples, nose and chin), botulinum toxin, thread lifting, lasers and scars, cellulite and body contouring, skin boosters, energy devices, skincare.
| Study (first author, year) | Journal | Topic | Key reported result |
|---|---|---|---|
| Kestemont, 2012 | Journal of Drugs in Dermatology | HA filler, cheeks (6 months) | 67.7% of week-3 volume maintained at month 6 on 3D analysis |
| Ceinos, 2016 | Journal of Esthetic and Restorative Dentistry | Reliability of facial and dental measurements | ICC 0.732–0.976 for facial measurements |
| Casanova, 2017 | Aesthetic Plastic Surgery | 1210-nm laser, post-operative scars (RCT, 1 year) | Better volume, surface and roughness vs control at 1 year |
| Kerscher, 2017 | Clinical, Cosmetic and Investigational Dermatology | Two HA fillers, midface, split-face (18 months) | CPM-26 non-inferior to VYC-20 at month 3; greater volume at every time point |
| Rappl, 2018 | Aesthetic Plastic Surgery | Botulinum toxin A, glabellar lines (90 days) | −24% static glabellar lines at day 90 |
| Moradi, 2020 | Journal of Cosmetic Dermatology | Topical body treatment after cryolipolysis or radiofrequency | Greater abdominal volume loss vs placebo, p = 0.0078 at week 12 |
| Machado, 2020 | Aesthetic Plastic Surgery | Laser-assisted delivery, periorbital wrinkles | Vitamin C + growth factors superior to vitamin C alone (p < 0.01) |
| Machado, 2021 | Scientific Reports | 3D vs IGAIS clinical scale, wrinkles and scars | 3D correlated with the scale; no false gains in untreated controls |
| Machado, 2021 | Aesthetic Plastic Surgery | Laser-assisted delivery, scars | Both groups improved; growth factors added benefit (p < 0.01) |
| Wong, 2021 | Journal of Clinical & Experimental Dermatology Research | Prejuvenation, pigmentation (2 patients) | Measurable decrease in pigment count |
| Torres, 2021 | Kosmetische Medizin | HA filler, cheekbones, curved cannula (300 days) | Results better than baseline up to day 300 |
| Diaspro, 2021 | Dermatologic Therapy | Thread lifting, midface (350 days) | +5.59 mL at 120 days; +4.16 mL at 350 days |
| Chernoff, 2021 | Journal of Clinical and Cosmetic Dermatology | Sea salt exfoliation, ultrasound and LED | No adverse reactions reported |
| Tanzi, 2021 | PMID 34224601 | Acoustic subcision, cellulite (multicenter pivotal trial) | −29.5% mean cellulite reduction (56 participants) |
| Carruthers, 2021 | Aesthetic Surgery Journal | Topical body treatment vs bland moisturizer | Volar forearm roughness p = 0.004; most other differences not significant |
| Rogério, 2022 | Brazilian Dental Science | Full-face botulinum toxin, tissue repositioning (case report) | +1.59 mL left and +1.17 mL right cheekbone |
| Wu, 2023 | Plastic and Reconstructive Surgery – Global Open | IncobotulinumtoxinA, glabellar lines (phase 3) | 92.5% vs 95.1% responders; non-inferiority confirmed |
| Chernoff, 2023 | Journal of Cosmetic Dermatology | Exosomes and calcium hydroxylapatite (40 patients) | 16 of 20 infusion patients very satisfied, 4 satisfied |
| Germani, 2023 | Journal of Cosmetic Dermatology | Infraorbital hollows, "Toxin Lift" | 0.54 mm cranial skin displacement at 15 days |
| Fanian, 2023 | Journal of Dermatological Treatment | HA micro-filler, superficial wrinkles (146 randomized) | Wrinkle reduction vs control at day 75 and day 120 |
| Salti, 2023 | Dermatologic Surgery | XTRCL filler, midface (6 months) | Significant improvement in volume and skin quality |
| Durairaj, 2024 | Aesthetic Plastic Surgery | Diluted CaHA, buttock cellulite (24 participants) | −50.09% dimple depth; 54% fewer visible dimples at 14 weeks |
| Germani, 2024 | Aesthetic Surgery Journal Open Forum | Two HA fillers for lips (RCT) | Lip volume increase at 30 days with the OBT gel, P = .014 |
| Rogerio, 2024 | Journal of Oral Biology and Craniofacial Research | Deoxycholic acid by microcannula (case report) | −14.81 mL submental volume after two sessions |
| Vitale, 2024 | International Journal of Clinical Studies and Medical Case Reports | 675-nm laser, mixed melasma (case series) | Improved pigmentary and vascular components |
| Siquier-Dameto, 2024 | Dermatologic Surgery | DEFCL filler, midface (12 months) | Volume and skin quality maintained at 12 months |
| Kim, 2024 | Plastic and Reconstructive Surgery – Global Open | HA filler, temple hollowness (25 women) | 3D volume 0.86 mL at 3 months and 0.72 mL at 6 months |
| Ramirez, 2024 | n/a | Superficial ultrasound and diluted CaHA (pilot, 12 subjects) | Skin roughness improved significantly at week 24 (all P < 0.001) |
| Diaspro & Sito, 2025 | Surgeries (MDPI) | HA gel, mid-face (318 days, 39 patients) | 4.46 mL at 45 days; 1.23 mL still measured at 318 days |
| Nomoto, 2025 | Journal of Cosmetic Dermatology | Longevity serum, split-face (5 subjects) | Trend toward improved radiance, firmness and laxity; small sample |
| Salti, 2025 | Journal of Cutaneous and Aesthetic Surgery | DEFCL filler, midface (18 months, 50 women) | 94% global aesthetic improvement at month 18 |
| Yonsei University (Kim et al.), 2026 | International Journal of Molecular Sciences | Particulated human ADM skin booster (split-face and preclinical) | Greater skin-volume gain than HA control over 20 weeks |
| Son, 2026 | Aesthetic Surgery Journal Open Forum | HA filler YYS 720, nose and chin (18 months) | Chin volume 1.73 mL at month 18 (P = .0061) |
| Erlich, 2026 | Lasers in Medical Science | XERF dual-frequency radiofrequency (16 women) | Improved laxity and skin quality at 3 months (preliminary) |
| Espinosa, 2026 | Cureus | Jawline botulinum toxin, neck effect (case report) | Neck volume −6.92 mL and −2.41 mL (two sides) at 15 days |
3D lesion quantification and validation (basal cell carcinoma, HPV lesions, acne scars), plus clinical trials and imaging studies in psoriasis, onychomycosis, atopic dermatitis, skin hydration and AI-based acne grading.
| Study (first author, year) | Journal | Topic | Key reported result |
|---|---|---|---|
| Skvara, 2011 | Journal of Investigative Dermatology | Topical smoothened inhibitor, basal cell carcinoma in NBCCS (8 patients) | Most basal cell carcinomas responded vs vehicle |
| Skvara, 2012 | Skin Research and Technology | 3D stereovision camera validation | 55 µm accuracy, 8 µm precision, 0.999 correlation between injected and measured volumes |
| Sofen, 2015 | Journal of the American Academy of Dermatology | Vismodegib in operable basal cell carcinoma (phase II) | Complete histologic clearance 42%, 16% and 44% by cohort; primary endpoints not met |
| Hogendoorn, 2015 | Clinical Therapeutics (conference abstract) | 3D photography, skin lesion quantification (phantom) | Coefficient of variation ≤ 2.6% across operators, skin backgrounds and days |
| Gottlieb, 2017 | Journal of the American Academy of Dermatology | Secukinumab, palmoplantar psoriasis (GESTURE) | 33.3% clear or almost clear (300 mg) vs 1.5% placebo at week 16 |
| Petit, 2018 | Skin Research and Technology | 3D imaging, atrophic acne scars (31 patients) | ICC 0.98 repeatability; r = 0.77 with global severity ratings |
| Reich, 2019 | British Journal of Dermatology | Secukinumab, nail psoriasis (TRANSFIGURE) | NAPSI −63.2% at week 32 (300 mg) |
| Gottlieb, 2019 | British Journal of Dermatology | Secukinumab, palmoplantar psoriasis, 2.5 years | 59.2% clear or almost clear at 2.5 years (300 mg) |
| Rijsbergen, 2019 | Journal of the European Academy of Dermatology and Venereology | 3D photography, HPV-induced skin lesions | ICC ≥ 0.86 between raters; reproducibility CVs ≤ 2% |
| Bullock, 2020 | Proceedings of SPIE | Vitamin D and photodynamic therapy, basal cell carcinoma | 80% final clinical clearance of 45 lesions after three treatments |
| Gupta, 2021 | Journal of the American Academy of Dermatology | Topical terbinafine 10%, onychomycosis (phase 3) | 69.9% mycological cure vs 27.7% vehicle at week 52 |
| Cork, 2023 | Conference abstract | Dupilumab, skin barrier in children aged 6–11 | Non-lesional skin reached TEWL levels comparable to healthy skin at week 16 |
| Nguyen, 2024 | Journal of Drugs in Dermatology | Facial hydration heatmaps (pilot) | Hydration shifted from about 12–42 AU to 30–60 AU at 30 minutes |
| Bernhard, 2024 | n/a | Deep learning, acne severity grading | 66.67% test accuracy on a small, imbalanced dataset |
Wound area measurement, cutaneous lesion volume, and preclinical and protocol work in wound healing.
| Study (first author, year) | Journal | Topic | Key reported result |
|---|---|---|---|
| Chaby, 2017 | n/a | 3D imaging vs transparent tracing, venous leg ulcers (36 patients) | CCC 0.989 for ulcer area; 0.996 for the 4-week healing rate |
| Slopis, 2018 | Drugs in R&D | Everolimus, cutaneous lesions in neurofibromatosis-1 (phase II) | Significant surface volume reduction in 13% of lesions; p = 0.048 for average height |
| Wagner, 2018 | Preclinical study (mouse model) | Irradiated PBMC secretome, wound closure | Faster closure with the complete secretome in diabetic mice |
| Holbert, 2019 | Trials | Hydrogel dressing, pediatric burns (study protocol) | Protocol only, no results reported |
| Karner, 2020 | Scientific Reports | Fecal-bacteria wound infection model (mouse) | Significantly delayed wound healing (p < 0.05) |
A collection of 54 published studies (2011–2026) in which clinicians and researchers used 3D stereophotogrammetry to quantify clinical outcomes in aesthetics, dermatology and wound care. Many of them used LifeViz® 3D imaging.
The studies are published by independent investigators in 31 journals and conference proceedings, including Dermatologic Surgery, Aesthetic Plastic Surgery, Journal of the American Academy of Dermatology, Scientific Reports and the British Journal of Dermatology. Quartier Latin compiles and summarizes them; the findings are those of the original authors.
Aesthetics (35 studies), dermatology (14) and wounds (5).
Facial and body volume (in mL), soft-tissue displacement, wrinkle depth, skin roughness, scar volume and surface, lesion size and volume, and wound area.um dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Validation studies in the compendium report high reproducibility, for example ICC 0.732–0.976 for facial measurements (Ceinos 2016), ICC 0.98 for acne scar volume (Petit 2018) and CCC 0.989 against transparent tracing for ulcer area (Chaby 2017). See the full publications for methods and limitations.
LifeViz Mini (3D facial imaging), LifeViz Micro (skin micro-topography), LifeViz Infinity (3D body imaging) and DermaViz / LifeViz 2D (2D skin analysis). Older publications use previous names: QuantifiCare, 3D LifeViz Mini, LifeViz Micro or DermaPix. Quartier Latin S.A.S. is the former aesthetics division of QuantifiCare.
Always refer to the full original publication. Each summary in the PDF links to the source (DOI or PMID).
Check the full publication first, including its methods and limitations, before citing any result in a clinical or commercial context.
These summaries are provided for scientific information only. They report the methods, findings and conclusions of the original authors and are not claims made by Quartier Latin. Several studies evaluate third-party treatments; their inclusion does not imply endorsement of those products. Please refer to the full publications for complete methods, results and limitations.
Last updated: November 2026 (Edition October 2026) · © 2026 Quartier Latin S.A.S. · LifeViz® is a registered trademark.
3D SOLUTION
lorem ipsum
lorem ipsum
lorem ipsum
lorem ipsum